Anika Therapeutics | ANIK - Net Income


Anika Therapeutics reported $292K in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Abbott USD 928M 149M Jun/2026
Agenus USD 39.17M 49.8M Mar/2026
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Anika Therapeutics USD 292K 2.62M Dec/2025
Arrowhead Research USD -194.28M 61.55M Jun/2026
Enanta Pharmaceuticals USD -22.29M 93.76M Dec/2024
Halozyme Therapeutics USD 229.91M 79.86M Jun/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Insmed USD -13.24M 150.32M Jun/2026
Integra LifeSciences USD 4.48M 9.1M Jun/2026
J&J USD 5.53B 299M Jun/2026
Karyopharm Therapeutics USD -22.39M 79.81M Mar/2026
Ligand Pharmaceuticals USD 48.51M 61.85M Jun/2026
MacroGenics USD -36.77M 22.62M Mar/2026
Merit Medical Systems USD 41M 2.99M Mar/2026
Rigel Pharmaceuticals USD 12.42M 13.45M Sep/2024
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sanofi EUR 343M 1.27B Jun/2026
Smith & Nephew USD 303M 10M Jun/2026
Stryker USD 1.28B 531M Jun/2026
Veracyte USD 25.49M 3.22M Jun/2026
Xencor USD -21.73M 107.19M Jun/2026
Zimmer Biomet Holdings USD 198.3M 39.8M Jun/2026